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Abstract: 
The aim of the present study was to develop proliposomal formulations to enhance the oral bioavailability of agomelatin by 
improving solubility, dissolution and/or intestinal permeability. Proliposomal powder formulations were prepared using 
different ratios of agomelatin, phospholipon 90H and cholesterol by solvent evaporation method. The effect of phospholipid 
composition and drug:lipid ratio on in vitro performance of proliposomes was studied. Proliposomes were characterized for 
their particle size distribution, zeta potential, micromeritics, and entrapment efficiency. Further, the formulated proliposomes 
were subjected to in vitro drug release performance in both simulated gastric and intestinal fluid demonstrate improved 
dissolution characteristics compared to pure drug. Multimedia dissolution profiles were carried out to demonstrate enhanced 
dissolution characteristics compared to pure drug. Proliposomes provided enhanced agomelatin dissolution due to 
incorporation into the phospholipid bilayers and change in the physical state from crystalline to amorphous. These 
proliposomal formulations of agomelatin could provide improved oral bioavailability due to enhanced solubility, permeability 
and enhanced absorption. 
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INTRODUCTION: 
The carriers used to carry the drug to the site of action 
include immunoglobulins, serum proteins, synthetic 
polymers, lipid  vesicles  (liposomes),  microspheres,  
erythrocytes,  reverse  micelles,  niosomes,  
pharmacosomes  etc [1,2] . Liposome is a micro vesicle 
in which an aqueous volume is entrapped within the 
lipoidal membrane. Drug molecules can be entrapped 
within the lipid bilayer or in the aqueous space. Since the 
shelf life of liposomal suspensions can be limited, it 
would be useful to have a method of producing 
liposomes  quickly,  at  the  point  of  use  and  without  
excessive  manipulation.  These needs are met by the 
“proliposome” method [3]. Proliposomes (PLs) are 
covered with liposomal membrane when they are 
hydrated they produce liposomes. The concept of 
proliposomes was first introduced by Payne et al., in 
1875; they described proliposomes as dry free flowing 
granular product that forms liposomal dispersion on 
hydration or on contact with biological fluids in the body 
the stability problems of liposomes can be overcome by 
PLs without affecting their intrinsic characteristics. PLs 
are composed of phospholipid and water soluble porous 
powder [4] [5]. 
Agomelatine is a melatonin receptor agonist MT1 and 
MT2 and a 5-HT2C receptor antagonist. Agomelatine 
resynchronises circadian rhythms in animal models of 
delayed sleep phase syndrome. By antagonizing 5-HT2C 
receptors, it increases noradrenaline and dopamine release 
specifically in the frontal cortex. Therefore, it is 
sometimes classified as a norepinephrine–dopamine 
disinhibitor. It has no influence on the extracellular levels 
of serotonin. It also have positive phase shifting 
properties; it induces a phase advance of sleep, body 
temperature decline and melatonin onset. Low <5% 
Absolute bioavailability at the therapeutic oral dose and 
the inter individual variability is substantial.The chemical 
structure of agomelatine is very similar to that of 
melatonin. Where melatonin has an NH group, 
agomelatine has an HC=CH group. Thus melatonin 
contains an indole part, whereas agomelatine has a 
naphthalene bioisostere instead [6],[7]. 
According to BCS classification, the class II drugs have 
low solubility-high permeability and their absorption is 
dissolution rate limited. Several researchers are adopted 
for enhancing the dissolution behavior of BCS class II 
drugs by particle size reduction, crystal engineering, salt 
formation, solid dispersion, use of surfactant, 
complexation, increasing the surface area by micronization 
or nanonization, spray drying and microencapsulation [8]. 
Due to its low aqueous solubility and poor absolute 
bioavailability as it fall under BCS-II. Several strategies 
have been reported to enhance the dissolution properties 
and bioavailability of agomelatin by formulating it into 
different dosage forms. However, not yet reported relevant 
studies for oral administration of agomelatin proliposomal 
powders.  
 
MATERIALS & METHODS: 
Materials: 
Agomelatine was gifted from MSN Laboratories, India, 
Maltodextrin was gifted by Sigma Aldrich, Hyderabad, 
Cholesterol was purchased from SD Fine chemicals, 
Hyderabad Phospholipon 90H (highly purified 
hydrogenated soyphosphatidylcholine, 90% purity, HSPC) 
was a kind gift sample from Lipoid, Germany. Methanol 
and Chloroform were purchased from Merck Specialties 
Pvt. Ltd, Mumbai. All other chemicals used were of 
analytical grade and solvents were of HPLC grade. Freshly 
collected double distilled water was used all throughout 
the experiments. 
 
Methods: 
Preparation of calibration curve: 
 From prepared working standard stock solution of 
agomelatin (100μg/mL), the final concentrations of 
1μg/mL to 10μg/mL were prepared. The absorbance was 
measured at 236nm by using UV-Visible 
spectrophotometer and calibration curve was plotted as 
absorbance vs. Concentration. 
 
HPLC analysis of agomelatin 
The samples were assayed for agomelatin by using a 
stability-indicating HPLC method reported earlier [9]. The 
analysis of the drug was carried out on waters instrument 
with PDA waters 2998 detector with Empower software 
and hamilton syringe with 20μL, and a Lichrospher C18 
column (150×4.6mm, 5μm). Isocratic elution was carried 
out at a flow rate 1mL/min (UV detection- 236 nm). The 
mobile phase consisted of acetonitrile: methanol: water 
(55:25:20, v/v/v). The retention time was found to be 4.2 
min. Aliquots of 20 μL of each sample were spiked onto 
the column. The assay was linear (r2 = 0.9988), in the 
concentration range of 1–10μg/mL with the lowest 
detection. 
 
Preparation of agomelatine-loaded proliposome 
The thin film deposition method was adopted for 
formulation of proniosome powders reported in literature 
[10]. Table1 represented that the different proniosomal 
formulations compositions. accurately weighed quantities 
of lipid mixture 100 µM of Phospholipon 90H, and 
cholesterol at various ratios and drug (25mg) were 
dissolved in 20mL of solvent mixture containing 
chloroform and methanol (2:1).The resultant solution was 
transferred into a 250mL RB flask and maltodextrin was 
added to form slurry. The flask was attached to a rotary 
flash evaporator (Laborota 4000,Heidolph, Germany) and 
the organic solvent was evaporated under reduced pressure 
at a temperature of 45±2°C. After ensuring the complete 
removal of solvent, the resultant powders were further 
dried overnight in a vacuum oven at room temperature so 
as to obtain dry, free-flowing product. The obtained 
proliposome powders were sieved with a # 60 mesh screen 
(250µm).The obtained proniosome powders were stored in 
a tightly closed container at 2-8°C for further evaluation 
and characterization. The composition of different 
proniosomal formulations is represented in (Table1).  
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Table 1: Formulation codes of agomelatine loaded proliposomes 
Formulation 
code 
Phospholipon 90H: 
cholesterol 
Agomelatine 
(mg) 
Phospholipon 
90H (mg) 
Cholesterol 
(mg) 
Maltodextrin 
(mg) 
APL1 1:2 
25 
 
31.8 77.2 150 
APL2 1:1.5 25 31.8 57.9 150 
APL3 1:1 25 31.8 38.6 150 
APL4 1.5:1 25 47.7 38.6 150 
APL5 2:1 25 63.6 38.6 150 
 
Physico-chemical characterization of proliposome 
powders: 
Formation of liposomes from proliposome powders 
The optical microscopy was employed to visualize the 
derivation of liposomes upon hydration of proliposome 
powder. A cavity glass slide was taken and few mg of 
proliposomes powder was spread over it and followed by 
the addition of few µL of water along the side of the cover 
slip. The liposome formation on hydration of solid particle 
was monitored and photographed (Coslabs micro, India) 
and photograph was taken (Fig -2).  
 
Transmission Electron Microscope 
The proliposome powder was hydrated with distilled water 
and agitated manually for two minutes and the 
transmission electron microscope observations were 
performed [11]. A thin film was made on a carbon-coated 
copper grid by placing a drop of liposome dispersion. 
Before the film dried on the grid, it was negatively stained 
with sodium phosphotungstate solution (0.2%w/v); any 
excess solution was drained off with a filter paper. The 
grid was allowed to air dry, and samples were viewed 
under a transmission electron microscope (Tecnai G2, 
Jeol-100CX-II, and Netherlands). 
 
Micromeritics of proliposome powders and number of 
vesicles per mm3 
The measurement of the flow properties of proliposome 
powders was evaluated by determining the angle of 
repose, Carr’s compressibility index and Hausner’s ratio. 
The fixed funnel method was used for determination of 
angle of repose and Carr’s compressibility index and 
Hausner’s ratio were calculated from the bulk density and 
tapped density of the proliposome powders [12].  The 
number of vesicles formed after hydration of proliposome 
powder were counted by optical microscope using a 
haemocytometer and the number of vesicles per cubic mm 
was calculated by using the following formula [13]. 
 
 
 
Vesicle size and zeta potential 
The liposome dispersion was prepared by manually 
agitating proliposome powders with distilled water for few 
minutes. The mean size and polydispersity index of 
liposomes was determined by photon correlation 
spectroscopy using zetasizer Nano ZS90 (Malvern 
Instruments, Malvern, UK). Each sample was diluted to a 
suitable concentration with filtered distilled water and 
analysis was performed at 25°C with an angle of detection 
of 90°C. Zeta potential was also measured using Zetasizer 
Nano ZS90 (Malvern Instruments, UK) [14].  
 
Drug content and entrapment efficiency 
The drug content was determined by dissolving the 
proliposome powder (25 mg) in 50 mL of methanol. An 
aliquot of sample was taken in microcentrifuge tubes and 
followed by centrifugation at 10,000 rpm for 15 min. The 
supernatant was separated, suitably diluted with mobile 
phase and 20 μL of the sample was injected onto HPLC 
and quantified[15]. 
percentage entrapment of agomelatin in liposomes was 
calculated from the following equation: 
 % DE = (Total amount of drug added – Unentrapped 
drug) /Total amount of drug added) x 100     
 
 In vitro dissolution study 
In vitro dissolution study of proliposomal powders and 
pure drug was performed using USP type II (paddle) 
apparatus (Electrolab, TD L8, Mumbai, India) in 
multimedia dissolution media of pH 1.2, pH 4.5 and pH 
6.8 to maintain sink conditions. The volume of dissolution 
medium used was 900 mL and maintained at a temperature 
of 37 ± 0.5ºC with 50 rpm of paddle speed set at 
throughout the experiment. 5 mL of aliquot of was 
collected at predetermined time intervals at 15, 30, 60min 
and replaced with fresh dissolution medium to maintain 
constant volume and sink condition [16]. The samples 
were filtered by passing through 0.45 µm PVDF 
membrane filter (Millipore) and analyzed for agomelatin 
by HPLC at 236 nm. Cumulative % of drug released was 
calculated and plotted against time (t) [17].  
 
Solid state characterization 
Scanning Electron Microscopy (SEM) 
The surface morphology of the pure drug, maltodextrin 
and optimized proliposome powder (APL4) was 
investigated by scanning electron microscope (SEM) (S- 
4100, Hitachi, Japan). Samples were fixed on a brass stub 
using double sided adhesive tape and were made 
electrically conductive by coating with a thin layer of gold 
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and SEM images were recorded at 15 kev accelerating 
voltage. 
 
Differential Scanning Calorimetry (DSC) 
The physical state of the drug, unloaded proliposomes and 
optimized proliposome formulation was evaluated by 
performing DSC analysis of pure drug, unloaded 
proliposomes and optimized proliposome powder. The 
DSC curves of the samples were obtained by a differential 
scanning calorimeter (Mettler DSC 823e, Mettler- Toledo, 
Germany). Average sample weight of 5±2 mg were heated 
in hermitically sealed aluminum pan over a temperature 
range of 30°C to 230°C under a constant nitrogen gas flow 
of 70 mL/min at a heating rate of 10°C/min. The 
instrument was calibrated with indium (calibration 
standard, purity >99.9%) for melting point and heat of 
fusion. 
 
Fourier Transform Infrared (FT-IR) spectroscopy 
Infrared spectra of agomelatin, physical mixture and 
optimized proliposome powder formulation (APL4) were 
obtained using FT-IR spectrophotometer (Paragon 1000, 
Perkin Elmer, USA) by the conventional KBr pellet 
method. The scanning range was 4000–500 cm-1 and the 
resolution was 4 cm-1. 
 
Powder X-ray Diffractometry (PXRD) 
The PXRD patterns of agomelatin, maltodextrin and 
optimized proliposome powder formulation (APL4) were 
obtained using X-ray diffractometer (X’ Pert 
PROPANalytical, Netherlands). The measuring conditions 
were as follows: CuKα radiation, nickel filtered; graphite 
monochromator; 45 kV voltage; and 40 mA current with 
X’celerator detector. All samples were run at 1° (2θ) min-
1 from 3° to 45° (2θ). 
 
Stability Studies 
The formulations stored in clear glass vials with stopper, 
seal and were kept at room temperature and in refrigerator 
(2 ± 8 °C) for a period of 180 days. At definite time 
intervals (0, 30, 60, and 90,180 days), samples were 
withdrawn and hydrated with phosphate buffered saline 
pH (7.4) and observed for any sign of drug crystallization 
under optical microscope. Further the samples were also 
evaluated for % retention of agomelatin. 
 
RESULTS AND DISCUSSION: 
Preparation and physico-chemical evaluation of 
proliposomes 
The proliposomes proved to be the efficient carriers for 
improved oral delivery of lipophilic and amphiphilic 
drugs. In this study, the proliposomes have been prepared 
and evaluated their potential in improving the oral delivery 
of agomelatine. Several methods have been reported for 
the formulation of proliposomes which include crystal-
film method [18], film deposition on carrier method [19], 
freezing and drying method [20], powder bed grinding 
method [21], ﬂuided-bed method [22] and spray drying 
method [23],[24]. According to the feasibility in our 
laboratory, we have employed film deposition on carrier 
technique for the preparation of agomelatine containing 
proliposomes. 
The formation of liposomes after reconstitution depends 
on the ease of dispersibility of the carrier in aqueous 
fluids. Among the different carriers which include neusilin 
US2, sorbitol,  microcrystalline cellulose, etc. we preferred 
to use maltodextrin which confer porous structure and 
high surface area and enables the formulator for easy 
adjustment of amount of carrier required to support the 
lipid and also to prepare proliposomes with high surfactant 
to carrier mass ratios [25].  
The selection of phospholipid is important because it 
dictate the stability of the liposomes formed. Since the risk 
of oxidation is high in phosphatidylcholine due to the 
presence of unsaturated bonds in the fatty acid tails [26], 
hydrogenated soyphosphatidylcholine which is in powder 
form was used in the formulations. The high phase 
transition temperature and solid state renders more 
stability in GI fluids and augment the flow characteristics 
of the proliposomes respectively which is an important 
prerequisite for solid dosage forms. Apart from this, lipid 
to carrier load can be increased so that lipophilic drugs 
with high dose can be incorporated without any hindrance 
to the flow properties [27]. The proliposome concept has 
resolved many stability issues pertaining to the aqueous 
liposome dispersions. The maximum benefit of 
proliposomes can be achieved when it forms stable 
vesicles with high entrapment efficiency after hydration in 
the gastric fluids. In this perspective the structural lipid, 
cholesterol was used which is known to increase the 
stability of the bilayer with high amounts of drug 
entrapment. However the formation and stability of the 
formed liposomes is by and large dependent on the 
composition of phospholipid to cholesterol ratio because 
any alteration in their composition results in leakage of 
drug before the drug diffusion and fusion of vesicles with 
the GI membrane [28]. Therefore the effect of cholesterol 
was investigated by varying the HSPC to cholesterol ratio.    
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Construction of calibration curve 
 
 
Fig No 1 : Standard Graph of Agomelatin 
 
    
 
Fig. 2. Microphotographs showing A) proliposome powder B) formation of vesicles on maltodextrin after hydration 
with distilled water C & D) TEM image of liposome dispersion from reconstituted prolipsome powder upon manual 
agitation. 
Morphological evaluation of prepared proniosome 
powders by optical microscope 
The proliposomes upon hydration derive the formation of 
liposomes and was spontaneous suggesting a rapid 
conversion to liposomes on contact with physiological 
fluids in the body (Fig. 2A&2B). It is evident from the 
figure that in initial stages upon contact with water the 
lipids tend to form tubular structures and upon manual 
agitation they have deformed into small multilamellar 
vesicles acquiring spherical shape. Further the TEM 
analysis confirms the shape of vesicles formed after 
hydration of proliposomes (Fig. 2C & 2D).  
 
The micromeritics of the proliposome powders is vital in 
handling and processing operations because the dose 
uniformity and ease of filling into container is dictated by 
the powder flow properties. In general, three types of flow 
measurements can be used to evaluate the nature of 
powder flow i.e. angle of repose; Carr’s index and 
Hausner’s ratio and the results were depicted in Table 2. 
The smaller the value of angle of repose, lesser the internal 
friction or cohesion between the particles and greater the 
flow characteristics and vice-versa. It is apparent from the 
results that small angle of repose (<20°) assure good flow 
properties for proliposome powder formulations. In 
addition to angle of repose, Carr’s index and Hausner’s 
ratio were also less than 17 and 1.25 respectively ensuring 
acceptable flow for proliposome powder formulations 
(Table 2) [43]. The distinctive advantage of proliposome 
formulations can be speculated only when abundant 
numbers of vesicles are derived from hydration of 
proliposome powders in the gastrointestinal tract. Among 
all the formulations, the proliposome formulation (APL4) 
containing equimolar ratio of HSPC and cholesterol (1:1) 
demonstrate good number of vesicles (Table 3). This is in 
correlation with our earlier reports [44]. 
One of the important parameter for the vesicular systems 
is vesicle size and size distribution [45]. The mean size of 
the vesicles was in the range of 192±14 to 292±19 (Table 
3). The size of the vesicles seems to be dependent on the 
cholesterol concentration. The PI used as a measure of a 
unimodal size distribution was within the acceptable limits 
for all the proliposomal formulations (Table 3). The zeta 
potential of the proliposome formulations (APL1 to APL5) 
was between 6.8±2.7 to 7.9±1.6 mV (Table 3). Earlier 
reports suggest that the surface charge has a significant 
influence on the drug uptake by biological membrane due 
to electrostatic attraction or improved vesicle enterocyte 
interactions [46]. The classical liposomes carry a feeble 
charge and considered to be neutral and zeta potential 
(7.9±1.6mV) of liposomes formed from optimized 
formulation (APL4). 
A
   
B C 
 
D 
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Table 2: Flow properties of agomelatin loaded proliposome powder formulations. 
 
Formulation Angle of repose () Compressibility index Hausner’s ratio 
APL1 16.8±0.21 10.8±0.08 1.09±0.15 
APL2 19.2±0.23 12.4±0.06 1.18±0.19 
APL3 19.8±0.32 15.5±0.25 1.22±0.13 
APL4 18.1±0.35 16.2±0.37 1.17±0.21 
APL5 19.3±0.27 15.7±0.28 1.25±0.12 
 
 
Table 3: Physico-chemical characterization of agomelatin loaded proliposome formulations 
 
Formulation  
Size 
(nm) 
P.I 
Zeta potential 
(mV) 
Entrapment 
efficiency (%) 
No. of vesicles 
per mm3 x 103 
APL1 192±14 0.209 7.2±1.9 72.7±2.2 3.02 
APL2 209±13 0.198 7.6±2.3 82.2±1.6 3.81 
APL3 229±10 0.181 7.3±1.5 86.5±1.1 3.21 
APL4 256±12 0.192 7.9±1.6 95.9±1.6 4.14 
APL5 292±19 0.244 6.8±2.7 79.2±1.5 3.23 
 
Among different methods used for determination of 
entrapment efficiency, we have employed ultra-filtration 
technique because no dilution step is involved unlike 
dialysis and column chromatography. The entrapment 
efficiency of proliposome formulations was between 73 to 
96 % (Table 3). Our results envisage that the entrapment 
efficiency of agomelatin is dependent on the composition 
of liposomes. This can be owed to the decreased leakage 
of the drug because of high compactness and hydrophobic 
interactions making the bilayer more stable. Further the 
effective intercalation of hydrophobic drug, agomelatin 
within the hydrophobic core of the bilayer may enhance 
drug pay load [47]. Interestingly, the same findings we 
could not extrapolate with proliposome formulation 
(APL4) and in converse the entrapment value reduced 
(Table 3). The perturbation of the linear structure of 
bilayer and decreased packing space available for drug 
molecules might have resulted in expulsion of drug 
molecules [19].  
In-vitro dissolution study   
The dissolution profiles of proliposomes were shown in 
figure 3. The amount of agomelatin released from 
proliposomes was ranging between 65 to 87% and was 
higher compared to control (31 %). The dissolution 
efficiency of insoluble drug agomelatin has been 
significantly improved when encapsulated in 
proliposomes. This might be due to the enhanced 
solubility of agomelatin by phospholipid molecules or 
transformation of the crystalline state of the drug to 
amorphous state [31]. Further these results were consistent 
with the DSC and PXRD studies. However, we could not 
notice any remarkable change in the dissolution behavior 
with different proliposome formulations . 
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Fig No.3: Dissolution profile of agomelatin released from proliposome powder formulations 
 
 
Solid State Characterization 
The surface morphology of the pure drug, maltodextrin 
and proliposome powders were examined by SEM and the 
images are represented in figure 4. The absence of typical 
crystalline structures of agomelatin in proliposome 
formulation indicates the transformation of drug to 
amorphous or molecular state. Further, the porous 
structure of maltodextrin as evident in figure was illegible 
in proliposome powders because of the deposition of 
phospholipids on the surface of maltodextrin.   
The thermotropic behavior and the physical state of the 
drug in proliposome powders were evaluated by 
performing DSC analysis. The DSC thermograms of 
agomelatin, unloaded proniosomes, loaded proniosomes 
optimized formulation (APL4) were recorded Fig. 5A-C. 
The unloaded proniosomes exhibited a difused peak at 
73.9°C, The loaded proniosomes exhibited a difused peak 
at 68.0°C corresponding to its melting point. The absence 
of conspicuous peak in proliposome formulation over the 
melting range of agomelatin unravels the transformation of 
the physical state of the drug (crystalline to amorphous) 
which was further confirmed by PXRD analysis.       
The PXRD patterns of agomelatin, maltodextrin and 
proliposome powder were represented in figure 6A-C. The 
pure drug showed numerous characteristic high intensity 
diffraction peaks at 2θ of 18.6, 19.7, 20.9, 24.1 and 44.1 
demonstrating the crystalline nature of the drug. The 
absence or reduced intensities of characteristic agomelatin 
peaks in proliposome formulation suggest the change in 
physical state i.e. amorphization of drug.  
 
Figure 7 A-C illustrates the FT-IR spectra of agomelatin, 
physical mixture and proliposome formulation (APL4). 
The pure drug agomelatin exhibit characteristic peaks 
bands at 1542.56 (N-H Bend) 1211.32, 1026.05 (C-N 
Stretch (alkyl)), 1297.46, 1250.36 (C-N Stretch (aryl)), 
1026.05, 1211.32, 1250.36, 1297.46 (C-O-C Stretch), 
3652.48, 3546.03 (O-H Stretch), 1645.45, 1697.93 (C = C 
Stretch), 3446.03 (N-H Stretch), 1211.32, 1026.05 (C-O 
Stretch). The peaks at1542.56 (N-H Bend ), 1211.32, 
1026.05 (C-N Stretch (alkyl)), 1297.46, 1250.36 (C-N 
Stretch (aryl) ), 1026.05, 1211.32, 1250.36, 1297.46 (C-O-
C Stretch),1645.45, 1697.93 (C = C Stretch),1211.32, 
1026.05 (C-O Stretch), were disappeared in proliposome 
formulation and the intensity of peaks at 3478.87, 3535.43 
(O-H Stretch), 3478.87 (N-H Stretch) was reduced in 
proliposome formulation. The peaks 1645.45, 1697.93 (C 
= C Stretch),1297.46, 1250.36 (C-N Stretch (aryl) ) and 
1542.56 (N-H Bend ), were disappeared in proliposome 
formulation and the intensity of peaks at 1148.02, 
1078.70(C-N Stretch (alkyl)), 1078.70, 1148.02(C-O-C 
Stretch), 3547.02, 3439.12(O-H Stretch), 3439.12, 
3337.42 (N-H Stretch),1078.70, 1148.02 (C-O Stretch) 
was reduced in proliposome formulation However no 
additional peaks in proliposome formulation indicate the 
absence of chemical interaction between the drug and 
formulation ingredients.  
 
 
IAJPS 2017, 4 (05), 1205-1215                       Pradeep Kumar Y et al                        ISSN 2349-7750 
 w w w . i a j p s . c o m  
 
Page 1212 
         
Fig.4. SEM images of (A) Agomelatin (B) Maltodextrin (C) Proniosome powder (APL4). 
 
Fig. 5A. DSC thermogram of Agomelatin   Fig.5B. DSC thermogram of unloaded proliposomes 
 
 
 
Fig. 5C. DSC thermogram of optimized proliposomes APL4 
 
     
 
Fig.6. [A]Powder X-ray diffraction pattern of Agomelation, [B]Maltodextrin, [C]optimized Proliposome 
formulation APL4 
 
A B C 
A 
B 
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A B C 
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Fig No.7. [A] FT-IR characteristic peaks of pure Agomelatine,  FigNo.7. [B] FT-IR 
characteristic peaks of physical mixture 
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FigNo.7. [C] FT-IR characteristic peaks of optimized Proliposome formulation [APL4]  
Stability study  
The physical appearance % retention of agomelatin was 
monitored for the optimized proliposome powder 
formulation (APL4) upon storage at refrigerated and 
ambient room temperature for a period of 180 days. At 
definite time intervals, the proliposome powder was 
hydrated to form liposomes and we could observe the 
formation of vesicles without any signs of drug 
crystallization. The entrapment efficiency was also 
monitored and the results indicate that there was no 
appreciable change in the % retention of agomelatin when 
stored at refrigerated temperature (Fig. 8) (Table No: 4). In 
addition, the formulation was destabilized at room 
temperature resulting in drug leakage with decreased % 
retention. The stability studies suggest that the 
proliposome formulation was comparatively less stable 
when stored at room temperature compared to refrigerated 
conditions. 
 
Table 4: Percentage potency of agomelatin in proliposome powder formulation (APL4) upon storage in 2-8° and at 
room temperature. 
Time (Days) Potency (%) at 2-8°C Potency (%) at 25°C 
0 99.8 99.8 
30 99.5 91.50 
60 98.4 86.20 
90 98.2 80.60 
180 98.2 75.20 
 
A 
B 
C 
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Fig No.8. Percentage retention of agomelatin in proliposome powder formulation (APL4) upon storage in refrigerator 
and at room temperature 
 
 
CONCLUSION: 
The agomelatin proliposomes were prepared by film 
deposition method using maltodextrin as carrier at varying 
ratios of HSPC and cholesterol. The formulation 
containing equimolar ratio of HSPC and cholesterol 
exhibited low size, high surface charge and entrapment 
efficiency. The formulations possess good flow properties 
and the in vitro dissolution behavior was improved 
compared to control. The solid state characterization 
results suggest that the native crystalline state of the drug 
has been transformed to amorphous and molecular state. In 
conclusion, the improved oral delivery of agomelatin 
proves the potential of proliposomes as suitable carriers 
for poorly soluble drugs. However, further in vivo studies 
need to be conducted to prove the feasibility of 
proliposome carriers for enhanced bioavailability of 
agomelatin. 
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